KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Deffered Revenue (2019 - 2025)

Aquestive Therapeutics has reported Non-Current Deffered Revenue over the past 7 years, most recently at $19.4 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $19.4 million for Q4 2025, down 3.07% from a year ago — trailing twelve months through Dec 2025 was $19.4 million (down 3.07% YoY), and the annual figure for FY2025 was $19.4 million, down 3.07%.
  • Non-Current Deffered Revenue for Q4 2025 was $19.4 million at Aquestive Therapeutics, down from $19.7 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for AQST hit a ceiling of $33.1 million in Q2 2023 and a floor of $4.7 million in Q1 2021.
  • Median Non-Current Deffered Revenue over the past 5 years was $19.8 million (2025), compared with a mean of $20.3 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 341.13% in 2022 and later crashed 38.22% in 2025.
  • Aquestive Therapeutics' Non-Current Deffered Revenue stood at $7.1 million in 2021, then soared by 341.13% to $31.4 million in 2022, then increased by 2.95% to $32.3 million in 2023, then tumbled by 38.15% to $20.0 million in 2024, then dropped by 3.07% to $19.4 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $19.4 million (Q4 2025), $19.7 million (Q3 2025), and $19.9 million (Q2 2025) per Business Quant data.